WP_Query Object
(
[query] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
)
[query_vars] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] => all
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] =>
[comments_per_page] => 50
[no_found_rows] =>
[order] =>
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wp_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.ID
FROM wp_posts
WHERE 1=1 AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
ORDER BY RAND()
LIMIT 0, 3
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 4906
[post_author] => 4
[post_date] => 2025-07-17 10:27:09
[post_date_gmt] => 2025-07-17 14:27:09
[post_content] =>
The Redesignation brings $10 million in funding to drive innovation, company formation, and economic growth.
The Center for Biotechnology (CFB) has announced its re-designated as a Center for Advanced Technology (CAT) by Empire State Development's Division of Science, Technology and Innovation (NYSTAR), a recognition that comes with $1 million in annual funding over the next ten years. The $10 million commitment underscores the CFB’s leadership in accelerating life science innovation, supporting early-stage technology development, and fueling economic growth through start-up formation and industry partnerships.
“The Center for Biotechnology has served as a critical bridge between academic research and commercial success,” said Dr. Clinton Rubin, Director of the Center for Biotechnology. “This re-designation ensures we can continue to expand our impact, helping innovators bring breakthrough technology to market and strengthening New York’s position as a leader in the bioscience industry.”
Empire State Development President, CEO and Commissioner Hope Knight said, “NYSTAR’s Centers for Advanced Technology are vital to our strategic efforts to grow New York’s economy and the state’s greater innovation ecosystem. By investing in the industries of tomorrow, New Yorkers benefit today through dynamic partnerships that help to create new jobs, generate more revenues, and encourage more companies to establish a footprint in communities all throughout the state.”
The Center for Biotechnology is located on the campus of Stony Brook University (SBU), the flagship research institution within the prestigious State University of New York (SUNY) system. Stony Brook University is recognized as a national and global leader in life sciences research, biomedical innovation, and clinical care. Situated on Long Island, New York, Stony Brook has built a formidable reputation as a hub for cutting-edge scientific discovery and translational medicine. The Center for Biotechnology builds upon these strengths by providing cutting-edge programming and competitive financial support to advance biomedical innovation and emerging company growth.
“We are excited to build upon the successful foundation of strong entrepreneurial networks, infrastructure, and programming that we have built over the last four decades” said Dr. Diane Fabel, Chief Operating Officer at the Center for Biotechnology. “The impacts we have had during our last designation period include over $1B in total economic impact with more than 1000 jobs created, and driving more than $315M in follow-on funding. We are excited to see those numbers continue to grow when we celebrate fifty years of hard work at the end of this redesignation period”.
As part of the New York State CAT program, the CFB will continue to work with emerging and established companies across the state to de-risk early-stage technologies, advance both technology and company value, foster public-private collaboration, and provide critical infrastructure for the region’s growing life science ecosystem. Additionally, the CFB team will continue its efforts to develop a life sciences workforce to support the region's bio-innovation economy with a specific emphasis on sectors deemed important to the NYS economy.
Dowload the full press release here.
[post_title] => Center for Biotechnology Announces Redesignation as New York State Center for Advanced Technology
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => redesignation2025
[to_ping] =>
[pinged] =>
[post_modified] => 2025-07-21 14:51:44
[post_modified_gmt] => 2025-07-21 18:51:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4906
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 3308
[post_author] => 3
[post_date] => 2019-07-24 17:34:16
[post_date_gmt] => 2019-07-24 17:34:16
[post_content] => Awards support innovative research collaborations between academic faculty and regional bioscience companies.
The Center for Biotechnology at Stony Brook University has announced the recipients of the 2019-2020 Applied Research & Development (ARaD) awards. The ARaD Program is designed to help bridge the gap between the early-stage technology discovery and development capabilities of the academic community, and the later-stage commercial development interests of the bioscience industry.
The program currently provides matching funds on a competitive basis to support collaborations between Stony Brook University faculty and New York State corporate partners in all areas of medical biotechnology. The primary interest is in supporting development of technologies that will help companies hit commercially relevant milestones, and that have the potential to positively impact the New York State economy.
Projects supported this year include the further development of an Intensive Care Unit temporary pacemaker, a novel material platform to improve extracorporeal membrane oxygenation (ECMOs) in heart-lung machines, further development of skin brightening agents, and a novel therapeutic to treat Lung Cancer.
“Through our participation in the Applied Research and Development Program at the Center for Biotechnology, we have been able to access the expertise of Dr. Wei Lin in the Department of Biomedical Engineering to collaborate on strategic research projects” stated Linda Towler, CEO of Avery Biomedical Devices, a global leader in high reliability diaphragm pacemakers. “This research and development collaboration has allowed us to considerably accelerate our product development and we expect it to generate significant new revenue for the company downstream.”
“The Center for Biotechnology is thrilled to be able to continue to collaborate with New York State companies to help them develop commercially promising technologies that will lead to strategic partnerships, investment, corporate revenues, and job creation” said Diane Fabel, Director of Operations for the Center for Biotechnology. “The projects supported by this year’s Applied Research and Development awards exemplify the innovative science happening all around us both in our academic institutions and bioscience companies. The Center for Biotechnology is excited to be an engine promoting interactions between the two to help fuel the overall bioscience ecosystem in the region.”
The ARaD Program is part of a suite of programs and services provided by the Center for Biotechnology (CFB) focused on accelerating the development of biomedical technologies in order to have a positive impact on human health and society.
2019-2020 Applied Research and Development Awards
“Temporary Pacemaker” Avery Biomedical Devices & Dr. Wei Lin, Associate Professor, Biomedical Engineering, Stony Brook University
“c-VACNT material bio-interaction studies” CVD Equipment Corporation & Dr. Srinivas Pentyala, Professor and Director of Translational Research, Anesthesiology, Stony Brook Medical Center
“Evaluation of Hydrogenated Curcumins as Skin Brightening Agents with Novel Antimelanogenic and Antioxidant” BioCogent, LLC & Dr. Sandford Simon, Professor, Biochemistrty & Cell Biology and Pathology, Stony Brook University
“Evaluation of small molecule Bax activators in mouse models of lung cancer” PHD Biosciences & Dr. Thomas Zimmerman, Assistant Professor, Director, Division of Laboratory Animal Resources, Stony Brook University; Attending Veterinarian, Brookhaven National Laboratory; Attending Veterinarian, Cold Spring Harbor Laboratory.
Click here for PDF version of announcement.
[post_title] => CFB Announces Annual Applied Research and Development Awards
[post_excerpt] => Research and development collaborations between Stony Brook University faculty and New York State corporate partners include projects furthering the development of an Intensive Care Unit temporary pacemaker and a novel material platform to improve ECMOs in heart-lung machines, among others.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => arad2019-2020
[to_ping] =>
[pinged] =>
[post_modified] => 2019-07-24 17:38:50
[post_modified_gmt] => 2019-07-24 17:38:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3308
[menu_order] => 90
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 186
[post_author] => 1
[post_date] => 2013-07-12 13:15:11
[post_date_gmt] => 2013-07-12 13:15:11
[post_content] => A licensing agreement has been reached between the Research Foundation for SUNY and Biodex Medical Systems for Mobility Assist, a device that was invented and patented Dr. Anurag Purwar at Stony Brook University that will help people who have trouble standing up or sitting down become more independently mobile. The Center for Biotechnology was instrumental in bringing together Dr. Purwar with Biodex Medical System as a potential commercialization partners at the 2012 Long Island Innovation Boot Camp/Pre-Seed Workshop. The Center for Biotechnology also facilitated a Technology Accelerator Fund application for Dr. Anurag Purwar for the project entitled: ?A Mobility Assist Sit to Stand Device to Improve Quality of Life and Independence for Persons with Functional Limitations.? Biodex Medical System and the Center for Biotechnology provided matching funds to aid in the commercialization of this technology.
Mobility Assist, which will be manufactured at the Biodex plant in Shirley, New York and be available to patients in 2014, will be marketed to physical and occupational therapists as well as assisted living facilities, hospitals, and nursing homes to increase mobility among patients and residents.
[post_title] => Fostering Growth
[post_excerpt] => Through strategic guidance and supportive programs, the Center for Biotechnology has helped entrepreneurs and companies de-risk and reach their next level.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => crowd-control
[to_ping] =>
[pinged] =>
[post_modified] => 2014-09-02 18:44:21
[post_modified_gmt] => 2014-09-02 18:44:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/new/?p=186
[menu_order] => 232
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 2153
[post_author] => 3
[post_date] => 2016-04-21 12:57:02
[post_date_gmt] => 2016-04-21 12:57:02
[post_content] => Stony Brook University-led initiative to accelerate commercialization of biomedical discoveries
STONY BROOK, AND MANHASSET, N.Y. – April 21, 2016 – The Center for Biotechnology at Stony Brook University and the Feinstein Institute for Medical Research, the research arm of Northwell Health, announced that the Feinstein Institute will be joining the Long Island Bioscience Hub (LIBH).
Established with a National Institutes of Health grant in 2015, Stony Brook's Center for Biotechnology is the lead administrative institution for the LIBH, an NIH-designated Research Evaluation and Commercialization Hub (REACH). It is one of three such Hubs in the country, the mission of which is to accelerate the translation of biomedical discoveries into new drugs, devices, and diagnostics to enhance health and improve patient care. The Feinstein Institute joins LIBH members Stony Brook University, Brookhaven National Laboratory and Cold Spring Harbor Laboratory. The addition of the Feinstein Institute fulfills one of the Hub’s goals of coordinating comprehensive technology commercialization efforts across all four major bioscience research institutions on Long Island.
“We look forward to working with the Feinstein Institute, and their involvement in the Long Island Bioscience Hub further enriches the region’s burgeoning innovation economy and entrepreneurial ecosystem,” said Clinton Rubin, PhD, Director of the Center for Biotechnology. “The Feinstein Institute is a world leader in multiple areas of biomedical research, and their expertise will complement the groundbreaking work being done at Stony Brook, Brookhaven Lab, and Cold Spring Harbor.”
“The Feinstein Institute’s focus is on advancing science, treating disease, and bringing healthcare innovations to patients,” stated Dr. Kevin Tracey, President and Chief Executive Officer of the Feinstein Institute. “Our partnership in the Long Island Bioscience Hub will help ensure that scientific breakthroughs emerging from our research enterprise progress into the commercial sector where they can ultimately impact patient care. We see the Long Island Bioscience Hub as a great opportunity to accomplish our mission.”
The LIBH is connected to a network of National Institutes of Health-designated “proof of concept” centers that include the three REACH centers and three additional National Centers for Accelerated Innovation. Collectively, they are developing best practices for the commercialization of academic innovations. The Hubs & Centers also have access to resources at the federal level including the US Patent & Trademark Office, Food & Drug Administration, and Centers for Medicare & Medicaid Services to provide guidance at the earliest stages of technology development.
The LIBH will provide funding for feasibility and proof of concept studies at the four Long Island partner institutions, and coordinate access to expertise in areas required for early stage technology development, including scientific, regulatory, business, legal, and project management. The Hub will also facilitate introductions to strategic industry partners and early stage investors. The LIBH announced its first round of technology development awards in December 2015, committing approximately $900,000 to thirteen projects. The second round of funded projects is expected to be announced in April 2016.
In addition to the Long Island Bioscience Hub’s institutional partners, support for the initiative has been provided by the Research Foundation of SUNY and Empire State Development. Total investment in the Hub over the next three years exceeds $8 million.
Download a PDF of the press release here.
[post_title] => Long Island Bioscience Hub Welcomes Feinstein Institute
[post_excerpt] => The Feinstein Institute for Medical Research, the research arm of Northwell Health, has joined the Long Island Bioscience Hub (LIBH). The addition of the Feinstein Institute fulfills one of the Hub’s goals of coordinating comprehensive technology commercialization efforts across all four major bioscience research institutions on Long Island.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => libh-welcomes-feinstein-institute
[to_ping] =>
[pinged] =>
[post_modified] => 2016-05-04 18:22:47
[post_modified_gmt] => 2016-05-04 18:22:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2153
[menu_order] => 184
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4906
[post_author] => 4
[post_date] => 2025-07-17 10:27:09
[post_date_gmt] => 2025-07-17 14:27:09
[post_content] =>
The Redesignation brings $10 million in funding to drive innovation, company formation, and economic growth.
The Center for Biotechnology (CFB) has announced its re-designated as a Center for Advanced Technology (CAT) by Empire State Development's Division of Science, Technology and Innovation (NYSTAR), a recognition that comes with $1 million in annual funding over the next ten years. The $10 million commitment underscores the CFB’s leadership in accelerating life science innovation, supporting early-stage technology development, and fueling economic growth through start-up formation and industry partnerships.
“The Center for Biotechnology has served as a critical bridge between academic research and commercial success,” said Dr. Clinton Rubin, Director of the Center for Biotechnology. “This re-designation ensures we can continue to expand our impact, helping innovators bring breakthrough technology to market and strengthening New York’s position as a leader in the bioscience industry.”
Empire State Development President, CEO and Commissioner Hope Knight said, “NYSTAR’s Centers for Advanced Technology are vital to our strategic efforts to grow New York’s economy and the state’s greater innovation ecosystem. By investing in the industries of tomorrow, New Yorkers benefit today through dynamic partnerships that help to create new jobs, generate more revenues, and encourage more companies to establish a footprint in communities all throughout the state.”
The Center for Biotechnology is located on the campus of Stony Brook University (SBU), the flagship research institution within the prestigious State University of New York (SUNY) system. Stony Brook University is recognized as a national and global leader in life sciences research, biomedical innovation, and clinical care. Situated on Long Island, New York, Stony Brook has built a formidable reputation as a hub for cutting-edge scientific discovery and translational medicine. The Center for Biotechnology builds upon these strengths by providing cutting-edge programming and competitive financial support to advance biomedical innovation and emerging company growth.
“We are excited to build upon the successful foundation of strong entrepreneurial networks, infrastructure, and programming that we have built over the last four decades” said Dr. Diane Fabel, Chief Operating Officer at the Center for Biotechnology. “The impacts we have had during our last designation period include over $1B in total economic impact with more than 1000 jobs created, and driving more than $315M in follow-on funding. We are excited to see those numbers continue to grow when we celebrate fifty years of hard work at the end of this redesignation period”.
As part of the New York State CAT program, the CFB will continue to work with emerging and established companies across the state to de-risk early-stage technologies, advance both technology and company value, foster public-private collaboration, and provide critical infrastructure for the region’s growing life science ecosystem. Additionally, the CFB team will continue its efforts to develop a life sciences workforce to support the region's bio-innovation economy with a specific emphasis on sectors deemed important to the NYS economy.
Dowload the full press release here.
[post_title] => Center for Biotechnology Announces Redesignation as New York State Center for Advanced Technology
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => redesignation2025
[to_ping] =>
[pinged] =>
[post_modified] => 2025-07-21 14:51:44
[post_modified_gmt] => 2025-07-21 18:51:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4906
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 282
[max_num_pages] => 94
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] =>
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] => 1
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] =>
[query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
[query_cache_key:WP_Query:private] =>
)
